Novo Nordisk’s stock has tumbled over 50% since its peak around a year ago, and it just ousted its CEO. Former employees say ...

The European Medicines Agency's safety committee has concluded that a potentially dangerous eye condition is a very rare side ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Novo Nordisk NVO has seen strong momentum in recent years, driven by the commercial success of its blockbuster semaglutide ...

Ozempic helped Novo Nordisk gain an early lead in the weight loss industry, but competition is nipping at the company's heels ...

Women employed at Novo Nordisk A/S are now paid more on average than the men working at the maker of blockbuster drugs Wegovy ...

This one-time weight-loss drug leader has suffered several setbacks lately. It isn't wise to count out this veteran ...

The former workers cited various reasons why they think Novo was cautious: its conservative culture and history of investing ...

We recently published a list of Was Jim Cramer Right About These 9 Stocks? In this article, we are going to take a look at ...

Novo Nordisk's (NVO) weight loss drug semaglutide (Ozempic, Wegovy, Rybelsus) is linked to a rare eye condition called NAION ...

A long-acting medicine developed by Novo Nordisk has been recommended as a treatment option for young people with growth ...